Invasive Group A Beta-Haemolytic Streptococcal Disease
Conditions
Brief summary
Introduction Since 2022 there are reports of a rapid increase in invasive group A streptococcal infections (iGAS) in children in some but not all European countries. Detailed information on this increase is lacking. Furthermore, an increase in other invasive infections as well as the emergence of novel pathogens and disease entities is seen, such as MIS-C and severe hepatitis of unknown origin. Aims To set up a European research network and describe the incidence, risk factors, clinical phenotypes, microbiology and resistance, treatment, and outcomes of iGAS in children across Europe. The network will subsequently be utilized for early alerting regarding the rise of other invasive and emerging infections in children. It will enable swift data collection pertaining to patient characteristics, presentation, progression, and treatment. Methods International, retrospective cohort and observational surveillance study of children 0-18y attending the ED or admitted to the hospital with iGAS. Clinical and microbiological data, national vaccination schedules, and COVID non-pharmaceutical interventions (NPIs) will be collected and compared between countries. Subsequently, the network will be employed to raise alarms regarding the surge of other invasive infections or emerging infections in children. Anonymous data about these novel infections will be collected, similar to the data from iGAS (clinical characteristics and microbiological data). The study is a non-profit study. Significance Our study will describe variation in the clinical phenotypes of iGAS, will aid in the understanding of its association with COVID NPIs and allow for comparison between countries. Furthermore, it will aid in early recognition of invasive and emergent infectious diseases in children and the reduction of outbreaks.
Interventions
OTHERNo intervention
no intervention, this is an observational study
Sponsors
European Society for Paediatric Infectious Diseases
Medical University of Graz
University Hospital Munich
National and Kapodistrian University of Athens
Mitera Hospital
Children's hospital Iceland
University of Padova
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Riga Stradins University
Maasstad Hospital
HagaZiekenhuis
Leiden University Medical Center
Wroclaw Medical University
University Medical Centre Ljubljana
Hospital Clínico Universitario de Santiago de Compostela
Hospital Universitario 12 de Octubre
Hospital Universitario La Paz
Gregorio Marañón Hospital
Karolinska Institutet
Imperial College London
University of Liverpool
Newcastle University
Noordwest Ziekenhuisgroep
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* All children (1 month-18 years) * attending the Emergency Department and/or admitted to the participating hospital - with iGAS infection or other invasive or emergent infectious disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| What is the incidence of iGAS in children before, during and after COVID NPIs in different European countries? | 2018-2025 |
| Is there a change in clinical phenotypes and outcome during these periods? | 2018-2025 |
Secondary
| Measure | Time frame |
|---|---|
| Can we identify risk factors for iGAS infection (e.g., preceding infections, age)? | 2018-2025 |
| Is there a change in emm types and other virulence factors during these periods | 2018-2025 |
| Can we use this research network for early alarming on other invasive and emergent infectious diseases in children | 2018-2025 |
| Can we explain differences between countries (e.g., differences in vaccination strategies, NPIs or emm types) | 2018-2025 |
| Are there differences in antimicrobial resistance between periods and between 4. Are there differences in antimicrobial resistance between periods and between countries | 2018-2025 |
Countries
Netherlands
Contacts
Primary ContactDorine Borensztajn, MD, PhD, MSc
Outcome results
None listed